GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
394.13
+1.12 (0.28%)
At close: Dec 5, 2025
0.38%
Market Cap 125.52B
Revenue (ttm) 62.07B
Net Income (ttm) 9.19B
Shares Out 318.47M
EPS (ttm) 28.85
PE Ratio 13.66
Forward PE 11.38
Dividend 10.00 (2.54%)
Ex-Dividend Date Sep 5, 2025
Volume 69,064
Average Volume 117,164
Open 397.00
Previous Close 393.01
Day's Range 391.00 - 398.00
52-Week Range 301.00 - 481.00
Beta 0.34
RSI 46.77
Earnings Date Mar 4, 2026

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc. [Read more]

Industry Pharmaceuticals
Sector Healthcare
Founded 2001
Employees 1,700
Stock Exchange Pakistan Stock Exchange
Ticker Symbol GLAXO
Full Company Profile

Financial Performance

In 2024, GlaxoSmithKline Pakistan's revenue was 61.19 billion, an increase of 23.21% compared to the previous year's 49.66 billion. Earnings were 6.54 billion, an increase of 1124.09%.

Financial Statements

News

There is no news available yet.